Jennifer M. O'sullivan

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Allele burden expansion in JAK2 V617F and CALR-mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment.

Journal: HemaSphere
Published: April 27, 2026

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.

Journal: Haematologica
Published: April 21, 2026

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Journal: British journal of haematology
Published: February 25, 2026

Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA.

Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA.

Journal: Science (New York, N.Y.)
Published: August 14, 2025

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Journal: Haematologica
Published: June 20, 2025

Tumor-Infiltrating Clonal Hematopoiesis.

Tumor-Infiltrating Clonal Hematopoiesis.

Journal: The New England journal of medicine
Published: April 23, 2025

QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

Journal: Leukemia
Published: March 19, 2025

Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety.

Treatment of Myeloproliferative Neoplasms With Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety.

Journal: EJHaem
Published: November 25, 2024

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.

A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.

Journal: Science translational medicine
Published: October 09, 2024

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.

Journal: British journal of haematology
Published: August 27, 2024

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.

Journal: HemaSphere
Published: April 01, 2024

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial.

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial.

Journal: Haematologica
Published: October 03, 2023
Showing 1-12 of 37

Last Updated: 09/26/2026